title: In reply to: Anti-HER2 neoadjuvant treatment may have an impact on discordance between preoperative core needle biopsy and surgical specimen in early breast cancer.
authors.affiliation: Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi Firenze, University of Florence, Florence, Italy. Electronic address: icro.meattini@unifi.it.
authors.forename: I
authors.initials: I
authors.lastname: Meattini
authors.affiliation: Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi Firenze, University of Florence, Florence, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Francolini
authors.affiliation: Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi Firenze, University of Florence, Florence, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Livi
authors.affiliation: Diagnostic Senology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
authors.forename: J
authors.initials: J
authors.lastname: Nori
mesh_terms: D062005:Biopsy, Large-Core Needle; D001707:Biopsy, Needle; D001943:Breast Neoplasms; D018270:Carcinoma, Ductal, Breast; D006801:Humans; D020360:Neoadjuvant Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases